Amphastar Pharmaceuticals (AMPH) AI Stock Analysis

• Market Cap: $1.12B
• Dividend Yield: N/A
• Average Volume (3M): 428.95K
• Price to Earnings (P/E): 9.1
• Beta (1Y): 0.70
• Revenue Growth: 1.37%
• EPS Growth: -18.10%
• Country: US
• Employees: 2,028
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.85
• Shares Outstanding: 46,495,075
• 10 Day Avg. Volume: 358,058
• 30 Day Avg. Volume: 428,950
• PEG Ratio: 0.73
• Price to Book (P/B): 2.46
• Price to Sales (P/S): 2.52
• P/FCF Ratio: 10.43
• Enterprise Value/Market Cap: 1.36
• Enterprise Value/Revenue: 2.12
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: 6.15
• 1Y Price Target: $31.75
• Price Target Upside: 31.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 67 Neutral
• Price Target: $26.00 ▲(7.53% Upside)

Amphastar Pharmaceuticals' overall stock score is driven by its strong valuation and financial stability, despite challenges in revenue growth and cash flow. The technical analysis indicates a bearish trend, but the stock's undervaluation presents potential upside. The earnings call provided mixed signals, with strategic expansions and product successes offset by competitive pressures and declining revenues.

Positive Factors

Manufacturing Expansion

Expanding manufacturing capacity enhances operational resilience and supports long-term growth by enabling Amphastar to meet increasing demand and reduce supply chain risks.

Product Performance

Strong performance of BAQSIMI indicates successful commercialization and market acceptance, contributing to revenue stability and growth potential.

R&D Investment

Increased R&D investment supports innovation and pipeline development, positioning Amphastar for future growth through new product introductions and regulatory approvals.

Negative Factors

Revenue Decline

A decline in revenue indicates potential challenges in maintaining market share and competitive positioning, which could impact long-term financial performance.

Margin Pressure

Decreasing gross margins due to pricing pressures from competition may affect profitability and limit the company's ability to invest in growth initiatives.

Product Sales Decline

Significant decline in epinephrine sales due to competition suggests market share erosion, which could weaken the company's revenue base and competitive advantage.

Amphastar Pharmaceuticals Business Overview & Revenue Model

Company Description

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

How the Company Makes Money

Amphastar Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which are categorized into generic and proprietary offerings. The company has established key revenue streams from its injectable products, including the sale of generic versions of high-demand medications. Additionally, Amphastar benefits from partnerships with healthcare organizations and distributors that enhance its market reach and product availability. The company's revenue model is supported by pricing strategies that take into account market demand and competition, as well as potential cost savings associated with its manufacturing processes. Moreover, the company is involved in the development of new products, which can lead to increased revenue through patent protections and exclusivity periods. Significant partnerships with other pharmaceutical firms also play a role in expanding Amphastar's product portfolio and distribution channels, contributing to its overall earnings.

Amphastar Pharmaceuticals Financial Statement Overview

Summary

Amphastar Pharmaceuticals demonstrates strong profitability with healthy margins and low leverage, contributing to financial stability. However, challenges include a decline in revenue growth and free cash flow, which may impact future investments.

Income Statement

Amphastar Pharmaceuticals shows strong profitability with a consistent gross profit margin around 50% and a net profit margin of approximately 18.7% in the TTM period. However, the revenue growth rate has declined by 1.1% in the TTM, indicating a potential slowdown in sales growth. The EBIT and EBITDA margins remain healthy, reflecting efficient cost management.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.06 in the TTM, indicating low leverage and financial stability. Return on equity is solid at 18.2%, suggesting effective use of equity to generate profits. However, the equity ratio is not explicitly provided, which limits a full assessment of asset financing.

Cash Flow

Operating cash flow to net income ratio is strong at 0.91, indicating good cash generation relative to net income. However, free cash flow has decreased by 25.3% in the TTM, which may impact future investments or debt repayments. The free cash flow to net income ratio remains healthy at 0.70, showing decent cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	720.28M	712.81M	644.39M	498.99M	437.77M	349.85M
Gross Profit	360.33M	373.86M	351.12M	248.86M	199.74M	143.34M
EBITDA	248.07M	277.31M	240.29M	146.16M	111.78M	30.19M
Net Income	134.71M	159.52M	137.54M	91.39M	62.12M	1.40M
Balance Sheet
Total Assets	1.62B	1.58B	1.51B	741.99M	671.53M	631.24M
Cash, Cash Equivalents and Short-Term Investments	231.75M	221.65M	256.81M	175.76M	136.67M	105.62M
Total Debt	47.77M	650.55M	623.64M	102.58M	104.66M	67.27M
Total Liabilities	857.85M	845.17M	873.49M	213.33M	226.01M	182.51M
Stockholders Equity	757.48M	732.30M	639.42M	528.66M	445.52M	402.31M
Cash Flow
Free Cash Flow	112.19M	172.34M	145.34M	65.15M	70.54M	23.41M
Operating Cash Flow	159.66M	213.39M	183.50M	89.18M	97.99M	57.27M
Investing Cash Flow	-60.41M	-124.93M	-649.12M	-32.78M	-28.67M	-36.41M
Financing Cash Flow	-101.36M	-80.95M	454.09M	-26.44M	-37.02M	-2.25M

Amphastar Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMPH, the sentiment is Negative. The current price of 24.18 is below the 20-day moving average (MA) of 24.74, below the 50-day MA of 27.08, and below the 200-day MA of 26.93, indicating a bearish trend. The MACD of -0.73 indicates Negative momentum. The RSI at 40.29 is Neutral, neither overbought nor oversold. The STOCH value of 67.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMPH.

Amphastar Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPN	―	$2.98B	46.47	6.38%	―	5.55%	1145.24%
AVDL	―	$1.81B	-563.33	-3.63%	―	132.35%	97.34%
COLL	―	$1.12B	34.18	16.16%	―	22.61%	-63.00%
AMPH	―	$1.12B	9.05	18.32%	―	1.37%	-18.10%
ANIP	―	$2.02B	-121.36	-2.82%	―	38.68%	-160.14%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCRX	―	$959.76M	―	-15.57%	―	2.25%	-301.59%

Amphastar Pharmaceuticals Corporate Events

Amphastar Signs $2.8M Research Agreement with Hanxin

On September 15, 2025, Amphastar Pharmaceuticals entered into a contract research agreement with Nanjing Hanxin Pharmaceutical Technology to develop Recombinant Peptide Research Cell Banks for the company. This agreement, valued at approximately $2.8 million, grants Amphastar exclusive rights to the developed cell banks and associated proprietary information. The deal was approved by the independent members of Amphastar’s Audit Committee due to potential conflicts of interest, as the company’s executives hold significant equity in Hanxin.

The most recent analyst rating on (AMPH) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.

Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights

Amphastar Pharmaceuticals’ recent earnings call painted a mixed picture of the company’s current standing. While there were notable achievements, such as the impressive performance of BAQSIMI and strategic manufacturing expansions, these were counterbalanced by declines in overall revenue and net income, alongside challenges from increased competition in key product lines.

Amphastar Pharmaceuticals Enters Strategic Licensing Agreement

On August 8, 2025, Amphastar Pharmaceuticals entered into a strategic licensing agreement with Nanjing Anji Biotechnology Co., Ltd. to develop and commercialize three proprietary peptides in the United States and Canada. This collaboration aims to enhance Amphastar’s pipeline in oncology and ophthalmology, with potential milestone payments to Anji reaching up to $453 million over the agreement’s term. The partnership underscores Amphastar’s commitment to advancing peptide therapeutics and expanding its market presence in high-growth areas.

The most recent analyst rating on (AMPH) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.

Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of complex generic and proprietary injectable, inhalation, and intranasal products, with a focus on hospital and urgent care settings.